ASCVD Risk Calculator

ASCVD Risk Calculator for Cardiology. The 2019 ACC/AHA primary-prevention guideline stratifies the 10-year output into four bands: low (<5%), borderline (5% to <7.5%), intermediate (7.5% to <20%), and high (>=20%). At >=7.5% a moderate-intensity statin is favored after a clinician-patient risk discussion; borderline risk warrants weighing risk-enhancing factors (family history, LDL >=160, chronic kidney disease, metabolic syndrome, inflammatory disease, South Asian ancestry, elevated Lp(a) or hs-CRP). When the decision is uncertain in the 5-20% range, a coronary artery calcium score of 0 can reclassify downward and defer statin therapy, while CAC >=100 or >=75th percentile supports treatment.

How this calculator works

The calculator applies the ACC/AHA Pooled Cohort Equations, sex- and race-specific (White vs. African American) Cox proportional-hazards models derived from pooled NHLBI cohort data (ARIC, CHS, CARDIA, Framingham Original/Offspring). It combines age, total and HDL cholesterol, systolic blood pressure (treated vs. untreated), diabetes, and current smoking to estimate the 10-year probability of a first hard ASCVD event, defined as nonfatal myocardial infarction, coronary heart disease death, or fatal/nonfatal stroke. Risk is computed as 1 minus the baseline survival raised to the exponentiated linear predictor centered on group mean values.

When to use this calculator

Use for primary-prevention adults aged 40-79 with LDL 70-189 mg/dL who do not already have clinical ASCVD, to anchor the statin and blood-pressure treatment discussion. It is designed for asymptomatic individuals and should NOT be used in patients with established ASCVD, LDL >=190 mg/dL, or diabetes with an indication for statins independent of score, since those groups are statin-eligible regardless. It is not validated below age 40 or above 79, and race is limited to a White/Black dichotomy that does not represent Hispanic, South Asian, or East Asian populations well.

Inputs used

  • Age
  • Sex
  • Cholesterol
  • Blood pressure
  • Diabetes
  • Smoking
  • Treatment status

Clinical interpretation

The 2019 ACC/AHA primary-prevention guideline stratifies the 10-year output into four bands: low (<5%), borderline (5% to <7.5%), intermediate (7.5% to <20%), and high (>=20%). At >=7.5% a moderate-intensity statin is favored after a clinician-patient risk discussion; borderline risk warrants weighing risk-enhancing factors (family history, LDL >=160, chronic kidney disease, metabolic syndrome, inflammatory disease, South Asian ancestry, elevated Lp(a) or hs-CRP). When the decision is uncertain in the 5-20% range, a coronary artery calcium score of 0 can reclassify downward and defer statin therapy, while CAC >=100 or >=75th percentile supports treatment.

Worked example

A 55-year-old White man, non-smoker, non-diabetic, total cholesterol 213 mg/dL, HDL 50 mg/dL, untreated systolic BP 120 mm Hg computes to roughly 5.3% 10-year ASCVD risk (borderline). Raising untreated systolic BP to 140 mm Hg and adding current smoking pushes the estimate above 15%, moving him from "consider statin after discussion" into the intermediate/high band where a moderate-to-high-intensity statin is favored.

Limitations and safety notes

The equations were derived from cohorts recruited decades ago and have been shown to overestimate risk by up to twofold in contemporary, higher-socioeconomic, and statin-era populations, which can drive overtreatment. Because age dominates the equation, most men over ~65 and women over ~70 cross the 7.5% threshold on age alone even with optimal risk factors. The model excludes family history, Lp(a), triglycerides, CAC, and any ancestry beyond non-Hispanic White or African American, systematically misclassifying South Asian (underestimate) and East Asian (overestimate) patients. It estimates only first events and is invalid in secondary prevention.

Frequently asked questions

Why does the calculator ask for race, and only offer White or African American?

The Pooled Cohort Equations were fit with separate coefficients for non-Hispanic White and African American adults because event rates and risk-factor weights differed in the derivation cohorts. Other ancestries were not represented, so the guideline advises using the White equations as an approximation while accounting for known offsets, e.g. treating South Asian patients as higher risk than the number suggests.

My patient is 78 and the score is 22% despite normal cholesterol and BP. Should I start a statin?

Age is the strongest term in the equation, so most older adults exceed the high-risk threshold on age alone. Use clinical judgment, life expectancy, polypharmacy, and a shared discussion rather than treating the number mechanically; a coronary artery calcium score can help refine the decision at the extremes of age.

Can I use this score for someone who already had a heart attack or stroke?

No. The equations estimate a FIRST hard ASCVD event in primary prevention. Patients with established clinical ASCVD are already high-risk and qualify for high-intensity statin therapy regardless of any calculated 10-year risk.

What does a coronary artery calcium (CAC) score add?

When the calculated risk falls in the borderline-to-intermediate range (roughly 5-20%) and the treatment decision is uncertain, CAC testing can reclassify. A CAC of 0 identifies a very low near-term risk group in whom a statin can often be deferred, whereas CAC >=100 or >=75th percentile for age/sex supports initiating therapy.

References

  • Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73. PMID: 24222018.
  • Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. PMID: 30879355.
  • Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64(10):959-68. PMID: 25190228.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: March 24, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

  • Prefer original validation studies for scoring systems and prediction tools.
  • Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
  • Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.

Related reviewed calculators